Chandigarh urges tight monitoring of MRPs in the Pharma Industry

It is possible that similar practices are occurring with other non-schedule formulations as well.

219
Medicine Tablet
Picture: Pixabay

Last Updated on June 8, 2023 by The Health Master

Monitoring of MRPs in the Pharma Industry

In an effort to combat unjust trade practices within the pharmaceutical sector, the UT health secretary has called upon the National Pharmaceutical Pricing Authority (NPPA) to conduct rigorous oversight of the maximum retail prices (MRPs) for specific non-schedule formulations, which are drugs not subject to direct price controls.

Ensuring Transparency and Fairness in the Pharmaceutical Market

The health secretary of Chandigarh has made this appeal to guarantee transparency and fairness in the pharmaceutical market while emphasizing the critical importance of maintaining affordable access to essential medications for all individuals.

This move is motivated by concerns regarding potential price manipulation and the necessity to shield consumers from exploitative practices.

The Role of the National Pharmaceutical Pricing Authority (NPPA)

The NPPA, operating under the Department of Pharmaceuticals, serves as a regulatory body responsible for implementing and enforcing the provisions outlined in the Drugs Price Control Order (DPCO).

Uncovering Price Discrepancies: A Case Study

On April 15, the health secretary, Yashpal Garg, conducted a discreet investigation by visiting three chemist shops located on the campus of GMSH, Sector 16, posing as a patient.

Each of these shops provided a different syrup containing the same salts:

  • Magaldrate,
  • Simethicone, and
  • Oxetacaine.

Upon further investigation by drug regulators, it was discovered that a manufacturer in Parwanoo, Solan, Himachal Pradesh, initially sold the “MCAIN” brand of syrup for ₹18 per bottle, but assigned an MRP of ₹267.

Shockingly, as the product traversed through the distribution chain, it was successively sold for ₹18, ₹25, ₹171, ₹190.72, and ultimately, for ₹226.95 to the consumer, even after applying a 15% discount.

This analysis revealed an astronomical 1483% increase in the syrup’s MRP from the manufacturer’s initial sale price.

Similarly, the brand “RICAINE” from a manufacturer based in Mohali was initially sold for ₹19 per bottle, with an MRP of ₹159—an 837% surge from the initial sale price.

Likewise, the brand “SUFIT-O,” produced by a manufacturer in Baddi, Solan, Himachal Pradesh, had an initial sale price of ₹18 per bottle, but boasted an MRP of ₹160, an astonishing 889% higher than the original sale price.

Urgent Action Needed to Address Unfair Trade Practices

The health secretary has highlighted the alarming MRPs observed for non-schedule formulations, which raise concerns about unfair trade practices by manufacturers and dealers.

It is possible that similar practices are occurring with other non-schedule formulations as well.

Garg has emphasized that manufacturers and dealers failed to inform the authorities about the MRPs, thereby urging a comprehensive investigation into the matter and the appropriate course of action.

Establishing a Pharmaceutical Price Monitoring Resource Unit

While Chandigarh is in the process of establishing a pharmaceutical price monitoring resource unit, a registered society has been formed for this purpose. However, it may take some time to initiate its operations, according to Garg.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news